Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
- 1 February 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (3) , 631-640
- https://doi.org/10.1038/sj.bjp.0703850
Abstract
1. This study was directed at exploring the structure-activity relationship for anandamide and certain of its analogues at the rat VR1 receptor in transfected cells and at investigating the relative extent to which anandamide interacts with CB(1) and vanilloid receptors in the mouse vas deferens. 2. pK(i) values for displacement of [(3)H]-resiniferatoxin from membranes of rVR1 transfected CHO cells were significantly less for anandamide (5.78) than for its structural analogues N-(4-hydroxyphenyl)-arachidonylamide (AM404; 6.18) and N-(3-methoxy-4-hydroxy)benzyl-arachidonylamide (arvanil; 6.77). 3. pEC(50) values for stimulating (45)Ca(2+) uptake into rVR1 transfected CHO cells were significantly less for anandamide (5.80) than for AM404 (6.32) or arvanil (9.29). Arvanil was also significantly more potent than capsaicin (pEC(50)=7.37), a compound with the same substituted benzyl polar head group as arvanil. 4. In the mouse vas deferens, resiniferatoxin was 218 times more potent than capsaicin as an inhibitor of electrically-evoked contractions. Both drugs were antagonized to a similar extent by capsazepine (pK(B)=6.93 and 7.18 respectively) but were not antagonized by SR141716A (1 microM). Anandamide was less susceptible than capsaicin to antagonism by capsazepine (pK(B)=6.02) and less susceptible to antagonism by SR141716A (pK(B)=8.66) than methanandamide (pK(B)=9.56). WIN55212 was antagonized by SR141716A (pK(B)=9.02) but not by capsazepine (10 microM). 5. In conclusion, anandamide and certain of its analogues have affinity and efficacy at the rat VR1 receptor. In the mouse vas deferens, which seems to express vanilloid and CB(1) receptors, both receptor types appear to contribute to anandamide-induced inhibition of evoked contractions.Keywords
This publication has 24 references indexed in Scilit:
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 2001
- Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and developmentExpert Opinion on Investigational Drugs, 2000
- The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)British Journal of Pharmacology, 2000
- Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid ReceptorsBiochemical and Biophysical Research Communications, 1999
- Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide AmidohydrolaseJournal of Medicinal Chemistry, 1999
- Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonistBritish Journal of Pharmacology, 1997
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997
- pA2 and receptor differentiation: A statistical analysis of competitive antagonismLife Sciences, 1979
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973